Lessons from the SWITCH trial: Changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC) Journal Article

   


Authors: Teo, M. Y.; Scher, H. I.
Article Title: Lessons from the SWITCH trial: Changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
Abstract: Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression. Here, we discuss the potential underlying mechanisms, including the activation of glucocorticoid receptors (GR) in progressive mCRPC and the implications for clinical practice. © 2018, Cancer Research UK.
Journal Title: British Journal of Cancer
Volume: 119
Issue: 9
ISSN: 0007-0920
Publisher: Nature Publishing Group  
Date Published: 2018-10-30
Start Page: 1041
End Page: 1043
Language: English
DOI: 10.1038/s41416-018-0239-y
PUBMED: 30344307
PROVIDER: scopus
PMCID: PMC6219496
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055549638&doi=10.1038%2fs41416-018-0239-y&partnerID=40&md5=2a1d44984e4191c86d412f9d4b6d3f86
Notes: Editorial -- Export Date: 3 December 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Howard Scher
    1129 Scher
  2. Min Yuen Teo
    104 Teo
Related MSK Work